JPWO2019195513A5 - - Google Patents

Claims (24)

Formula I:
[M _{x Do} A _p W _q ] A supramolecular metal coordination complex with _n , which is described in the formula.
M is a metal atom,
D is a biologically active moiety containing at least two functional groups capable of coordinating to a divalent metal.
A is a second biologically active moiety or adjuvant,
W is H ₂ O,
x is an integer from 1 to 10.
o is an integer from 1 to 10 and
p is zero or an integer from 1 to 10 and
q is zero or an integer from 1 to 20
n is a supramolecular metal coordination complex which is an integer of 2 or more. The complex according to claim 1, which is insoluble in water. The complex according to claim 1, which has a polymer structure. The complex according to claim 1, wherein the biologically active moiety exhibits control of release from the complex when administered to a patient. The complex according to claim 1, wherein the functional group contains a heteroatom forming a metal coordination bond. The complex according to claim 5, wherein the heteroatom is selected from nitrogen, oxygen, and sulfur. The complex according to claim 1, wherein the metal is selected from an s-block element, a transition metal, a p-block metal, a lanthanide, and an actinide. The complex according to claim 7, wherein the metal is selected from zinc, copper, magnesium, calcium, strontium, sodium, nickel, and bismuth. The complex according to claim 1, wherein the biologically active moiety comprises a first functional group and a second functional group. The complex according to claim 1, wherein the biologically active moiety comprises a first functional group, a second functional group, and a third functional group. The complex according to claim 1, wherein the adjuvant is selected from aromatic dicarboxylic acids, phenols, and catechols. The complex according to claim 11, wherein the adjuvant is tyrosine. The complex according to claim 1, wherein x and o have the same value. The complex according to claim 1, wherein x and o are different values. The biologically active moieties are triiodosilonin (T3), amoxycycline, cefotetan, frosemide, methotrexate, balsartan, chlortetracycline, demeclocycline, doxycycline, meclocycline, oxytetracycline, tetracycline, ciprofloxacin. , Danofloxacin, difloxacin, enoxacin, enlofloxacin, freroxacin, lomefloxacin, malvofloxacin, norfloxacin, perfloxacin, pipemidic acid, ofloxacin, and salafloxacin, and combinations thereof, according to claim 1. The complex according to claim 1, wherein the biologically active moiety is triiodothyronine (T3). [ Zn ₆ (T3) (tyr) ₅ ] _n , [Cu (T3) (H ₂ O)] _n , [Mg (T3) -2H ₂ O] _n , [Ca (T3) -2H ₂ O] _n , The complex according to claim 16, which is selected from [Sr (T3) -4H ₂ O] _n . A pharmaceutical composition comprising the complex according to claim 1 and a pharmaceutically acceptable carrier. 18. The composition of claim 18, wherein the composition exhibits control of release of the biologically active moiety. A pharmaceutical composition for treating a patient with a disease, which comprises the complex according to claim 1 in a therapeutically effective amount. The composition according to claim 20, wherein the disease is hypothyroidism. A method of increasing the mucosal adhesion properties of biologically active moieties, according to Formula I :.
[M _{x Do} A _p W _q ] _n (in the formula,
M is a metal atom,
D is a biologically active moiety containing at least two functional groups capable of coordinating to a divalent metal.
A is a second biologically active moiety or adjuvant,
W is H ₂ O,
x is an integer from 1 to 10.
o is an integer from 1 to 10 and
p is zero or an integer from 1 to 10 and
q is zero or an integer from 1 to 20
A method comprising forming a metal coordination complex (n is an integer greater than or equal to 2). The metal coordination complex is [Zn (T3) (H). ₂ O)] _n The metal coordination complex according to claim 8. The metal coordination complex is [Zn (T3) (H). ₂ O)] _n The method according to claim 22.